Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics rises on positive interim data for breast cancer drug

(Updates)
    ** Shares of drug developer eFFECTOR Therapeutics Inc
 EFTR.O  rise 19% to $0.62 
    ** Company announced positive interim data from a mid-stage
study evaluating combination therapy of its zotatifin in
patients with a type of breast cancer
    ** Says partial responses observed in 5 of 19 evaluable
patients treated with 0.07 mg/kg dose of zotatifin combined with
AstraZeneca Plc's  AZN.L  fulvestrant and Eli Lilly and Co's
 LLY.N  abemaciclib
     ** Adds that partial response observed in 1 of 3 patients
treated with 0.1 mg/kg dose of combined with fulvestrant
    ** Both combinations were generally well tolerated - EFTR
    ** Plans to report data from the completed dose escalation
in H2 
    ** Stifel upgrades stock to "buy" from "hold", raises PT to
$7 from $1.3
        ** Separately, co 
    raises
     $7.5 mln for 11.5 mln shares from institutional investor
  
        ** Deal values EFTR at $0.66/shr, a 23.8% premium over
last close
  
    ** Stock up 43% YTD

 (Reporting by Sriparna Roy and Aditya Samal in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))

Recent news on Effector Therapeutics

See all news